Salome Adam1,2, Lena Koch-Gallenkamp3, Heike Bertram4, Andrea Eberle5, Bernd Holleczek6, Ron Pritzkuleit7, Mechthild Waldeyer-Sauerland8, Annika Waldmann8,9, Sylke Ruth Zeissig10, Sabine Rohrmann2, Hermann Brenner3,11,12, Volker Arndt1. 1. Unit of Cancer Survivorship, Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. 2. Division of Chronic Disease Epidemiology, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. 3. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. 4. Cancer Registry of North Rhine-Westphalia, Bochum, Germany. 5. Bremen Cancer Registry, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany. 6. Saarland Cancer Registry, Saarbrücken, Germany. 7. Schleswig-Holstein Cancer Registry, Lübeck, Germany. 8. Hamburg Cancer Registry, Hamburg, Germany. 9. Institute of Social Medicine and Epidemiology, University Lübeck, Lübeck, Germany. 10. Cancer Registry of Rhineland-Palatinate, Mainz, Germany. 11. Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany. 12. German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Abstract
OBJECTIVE: Several therapies for localised prostate cancer (PC) are available; all yield similar survival rates. However, each therapy has significant side effects that can influence patients' health-related quality of life (HRQoL) in the long run. METHODS: The study sample included 911 survivors with localised PC, 5-15 years post-diagnosis who were identified from the population-based CAESAR + study in Germany. HRQoL was assessed using the EORTC QLQ-C30 and EORTC QLQ-PR25 questionnaires. The association between type of therapy and HRQoL was assessed with multivariable linear regression and global F-test adjusting for age, time since diagnosis and comorbidities. RESULTS: Overall, survivors treated with radical prostatectomy (RP) or radiotherapy (RT) alone reported the best HRQoL and the lowest symptom burden. Conversely, survivors treated with androgen deprivation therapy (ADT) (& RP/RT) or RP & RT (in combination) reported the worst HRQoL and the highest symptom burden. Significant differences among treatment groups in HRQoL were found for global health status (p = 0.041), social functioning (p = 0.007), urinary symptoms (p = 0.035), bowel symptoms (p = 0.017) and hormonal treatment-related symptoms (p < 0.001) among other symptoms. CONCLUSIONS: Long-term localised PC survivors formerly treated with a combination of RP and RT or with ADT report poorer HRQoL and more symptoms than patients treated with either RP or RT alone.
OBJECTIVE: Several therapies for localised prostate cancer (PC) are available; all yield similar survival rates. However, each therapy has significant side effects that can influence patients' health-related quality of life (HRQoL) in the long run. METHODS: The study sample included 911 survivors with localised PC, 5-15 years post-diagnosis who were identified from the population-based CAESAR + study in Germany. HRQoL was assessed using the EORTC QLQ-C30 and EORTC QLQ-PR25 questionnaires. The association between type of therapy and HRQoL was assessed with multivariable linear regression and global F-test adjusting for age, time since diagnosis and comorbidities. RESULTS: Overall, survivors treated with radical prostatectomy (RP) or radiotherapy (RT) alone reported the best HRQoL and the lowest symptom burden. Conversely, survivors treated with androgen deprivation therapy (ADT) (& RP/RT) or RP & RT (in combination) reported the worst HRQoL and the highest symptom burden. Significant differences among treatment groups in HRQoL were found for global health status (p = 0.041), social functioning (p = 0.007), urinary symptoms (p = 0.035), bowel symptoms (p = 0.017) and hormonal treatment-related symptoms (p < 0.001) among other symptoms. CONCLUSIONS: Long-term localised PC survivors formerly treated with a combination of RP and RT or with ADT report poorer HRQoL and more symptoms than patients treated with either RP or RT alone.
Authors: Salome Adam; Daniela Doege; Lena Koch-Gallenkamp; Melissa S Y Thong; Heike Bertram; Andrea Eberle; Bernd Holleczek; Ron Pritzkuleit; Mechthild Waldeyer-Sauerland; Annika Waldmann; Sylke Ruth Zeissig; Lina Jansen; Sabine Rohrmann; Hermann Brenner; Volker Arndt Journal: Support Care Cancer Date: 2019-11-18 Impact factor: 3.603
Authors: Frank J Penedo; Rina S Fox; Emily A Walsh; Betina Yanez; Gregory E Miller; Laura B Oswald; Ryne Estabrook; Robert T Chatterton; David C Mohr; Mark J Begale; Sarah C Flury; Kent Perry; Shilajit D Kundu; Patricia I Moreno Journal: Brain Behav Immun Date: 2021-03-15 Impact factor: 19.227
Authors: Nima Aghdam; Abigail Pepin; Michael Carrasquilla; Colin Johnson; Malika Danner; Marilyn Ayoob; Thomas Yung; Siyuan Lei; Brian T Collins; Deepak Kumar; Simeng Suy; John Lynch; Sean P Collins Journal: Front Oncol Date: 2020-01-22 Impact factor: 6.244